UID:
almahu_9948689679702882
Format:
X, 172 p. 18 illus. in color.
,
online resource.
Edition:
1st ed. 2021.
ISBN:
9783030690328
Series Statement:
Headache,
Content:
Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.
Note:
The CGRP family of neuropeptides and their receptors in the trigeminovascular system.-Pharmacology; where do the mAbs act, gepants vs mAbs -- Monoclonal Antibody Biology -- Guidelines for clinical trials -- Human Models -- CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders -- Galcanezumab -- Eptinezumab -- Erenumab -- Fremanezumab -- Potential side effects and pregnancy -- Real-world data, clinical practice so far -- Migraine vs Cluster headache and potential other indications.
In:
Springer Nature eBook
Additional Edition:
Printed edition: ISBN 9783030690311
Additional Edition:
Printed edition: ISBN 9783030690335
Additional Edition:
Printed edition: ISBN 9783030690342
Language:
English
DOI:
10.1007/978-3-030-69032-8
URL:
https://doi.org/10.1007/978-3-030-69032-8
Bookmarklink
